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Abstract
Background: Anxiety in dementia is common but not well studied. We studied the associations of anxiety
longitudinally in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB).
Methods: In total, 194 patients with a first-time diagnosis of dementia were included (n = 122 patients with
AD, n = 72 patients with DLB). Caregivers rated the patients’ anxiety using the Neuropsychiatric Inventory, and
self-reported anxiety was assessed with the anxiety and tension items on the Montgomery–Åsberg Depression
Rating Scale. The Mini Mental State Examination was used to assess cognitive outcome, and the Clinical
Dementia Rating (CDR)-Global and CDR boxes were used for dementia severity. Linear mixed effects models
were used for longitudinal analysis.
Results: Neither in the total sample nor in AD or DLB was caregiver-rated anxiety significantly associated with
cognitive decline or dementia severity over a 4-year period. However, in patients with DLB, self-reported anxiety was
associated with a slower cognitive decline than in patients with AD. No support was found for patients with DLB with
clinical anxiety having a faster decline than patients with DLB without clinical anxiety. Over the course of 4 years, the
level of anxiety declined in DLB and increased in AD.
Conclusions: Anxiety does not seem to be an important factor for the rate of cognitive decline or dementia severity
over time in patients with a first-time diagnosis of dementia. Further research into anxiety in dementia is needed.
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Background
Anxiety in dementia is common but not well studied. To
our knowledge, no longitudinal studies of the associa-
tions between anxiety and cognitive decline have been
done to date. The prevalence of anxiety in dementia is
estimated to range from 25 % to 71 %, and generalized
anxiety disorder seems to be the most common anxiety dis-
order [1]. People with co-morbid dementia and anxiety have
more impairment in activities of daily living, reduced quality
of life and more frequent nursing home admission than
people with dementia [2–4]. They also use more health care
services [5], and anxiety is associated with poorer relation-
ships with caregivers and increased caregiver burden [6].
In elderly individuals with no dementia, both depres-
sion and anxiety have been shown to be early predictors
of future cognitive decline [7, 8], and a more rapid
progression in cognitive decline over time has been
suggested, although the data are not conclusive [7, 9].
The risk of developing Alzheimer’s disease (AD) may
be up to 30 times higher among persons with mild cogni-
tive impairment (MCI) and anxiety [10]. A recently pub-
lished study showed that anxiety symptoms in amnestic
MCI predict conversion to AD to a greater degree than
depression, memory loss or hippocampal cortex atrophy
[11]. Moreover, it has been shown that anxiety is an
independent predictor of future cognitive decline and
not only via its relationship with depression, as often
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hypothesised in previous research [7, 12]. However,
others have reported that anxiety in elderly people is
not associated with increased risk of dementia or cognitive
decline [13, 14].
Few studies of anxiety in dementia with Lewy bodies
(DLB) have been done [15]. Ricci et al. [16] found that
anxiety was more common in patients with DLB than in
patients with AD, and this was later supported in a study
by our group [17]. Anxiety also is more common in
patients with DLB than in healthy control subjects and
is reported to be a risk factor for development of DLB
[18]. The severity of anxiety seems to be stable across
stages of dementia, except for a decrease at the terminal
stage [19, 20]. In a study of early-onset AD, the severity
of anxiety was increasing over 3 years, but the patients
were in different dementia severity stages at baseline [21].
Anxiety has overlapping symptoms with the dementia
disease itself, as well as with other behavioural and
psychological symptoms (BPSD) such as agitation and
depression. According to Seignourel et al. [19], there is
more support for that anxiety can be seen as a separate
clinical entity, and is distinctive from agitation. Depres-
sion and anxiety have a high co-morbidity rate in both
healthy elderly individuals and elderly persons with de-
mentia [17, 22]. Therefore, depression must be con-
trolled for to establish the independent contribution of
anxiety as a predictor of cognitive decline.
Identifying predictors of cognitive decline is important,
especially if an early intervention could reduce the speed
of cognitive decline, both in MCI and in dementia. We
investigated the association between anxiety and cognitive
decline during 4 years of follow-up in people with AD and
individuals with DLB.
Methods
Subjects
In total, 265 outpatients in clinics of old age psychiatry
and geriatric medicine in western Norway with a first-
time dementia diagnosis [Mini Mental State Examination
(MMSE) score >15] were recruited starting in 2005 and
followed annually. Patients with acute delirium or confu-
sion, terminal illness, or current or previous bipolar
disorder or psychotic disorder, or who were recently
diagnosed with a major somatic illness, were excluded
[23]. Follow-up examinations were conducted at the clinic
or in nursing homes. The study protocol was approved by
the Regional Committee for Medical and Health Research
Ethics in Western Norway. Written informed consent was
obtained from all participants in this study.
Measures
Dementia diagnosis
The diagnosis of dementia was based on criteria set
forth in the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition. AD was diagnosed according
to the criteria of the National Institute of Neurological
and Communicative Disorders and Stroke/Alzheimer’s
Disease and Related Disorders Association [24]. DLB
was diagnosed according to the revised consensus cri-
teria [25]. For further information, see the publication by
Aarsland et al. [23]. Two independent raters made the
diagnoses, and so far the diagnosis has been neuropatho-
logically confirmed in 36 cases.
Assessment of anxiety and depression
Symptoms of anxiety were rated on the basis of informa-
tion obtained from a caregiver using Neuropsychiatric
Inventory (NPI) [26] subscale E (Anxiety). On the NPI,
symptoms are assessed for the previous 30 days, rating
frequency (score 1–4) and severity (score 1–3). Frequency
and severity are multiplied to obtain a sum score. A score
above 4 is generally seen as clinically significant [27] and
was used to identify DLB cases with clinical anxiety.
In the present study, both categorical (caseness, pres-
ence of clinically significant anxiety) and dimensional
scores were used.
Patients’ own perceptions of anxiety were measured
with the anxiety item on the Montgomery–Åsberg
Depression Rating Scale (MADRS) [28]. The MADRS
items are rated from 0 to 6. The anxiety item (item 3)
addresses “feelings of ill-defined discomfort, edginess,
inner turmoil, mental tension mounting to either panic,
dread or anguish” during the previous 3 days. Ratings of
the MADRS and the NPI were conducted independently.
Caregiver-rated depression was measured with NPI
subscale D (Depression), and self-reported depression
was measured using MADRS.
Cognitive screening and dementia severity rating
The outcome measure—progression of dementia—was
measured using two scales. The MMSE [29] is a brief
test used to screen for cognitive impairment. The Clinical
Dementia Rating (CDR) [30] is used to assess the severity
of dementia on a scale from 0 to 3 (CDR-Global). The
CDR scale also comprises six cognitive and practical do-
mains (CDR boxes): Memory, Orientation, Judgement and
Problem-Solving, Community Affairs, Home and Hobbies,
and Personal Care.
Statistical analyses
Statistical analyses were performed using IBM SPSS 22.0
software (IBM, Armonk, NY, USA) and the R statistical
software package [31]. Differences between AD and DLB
at baseline were analysed with Mann–Whitney U tests
because the variables were not normally distributed, and
by Pearson χ2 tests for categorical data. Longitudinal
analysis was done with linear mixed effects models using
MMSE and CDR as dependent variables. For some
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outcomes, models with both random intercept and slope
were used; for others, random intercept was sufficient
according to model fit criteria. For longitudinal analyses of
outcomes with very few categories, the different CDR
(box) scores, the assumption of a normally distributed
outcome poses a problem. To overcome this, we dichoto-
mized the CDR scores and employed mixed effects logistic
regression to analyse the probability of a CDR score of 2
or greater as a function of time, anxiety, depression and
possibly other covariates.
Results
Patients diagnosed with probable or possible AD (n = 122)
and DLB (n = 72) were included in the analysis (see
flowchart of study inclusion in Fig. 1). At baseline,
patients with AD and patients with DLB did not differ in
demographic and clinical variables, except that there were
more women in the AD group and higher NPI total score
in the DLB group (see Table 1).
We found no significant interaction between time
and anxiety—neither caregiver-rated nor self-reported
anxiety—on the MMSE, CDR-Global or CDR boxes.
There was no significant interaction between diagnostic
group, time and anxiety (caregiver-rated or self-reported)
on the MMSE, CDR-Global or CDR boxes, except for an
interaction between diagnostic group, time and MMSE for
self-reported anxiety (p = 0.039), even after controlling for
depression and/or total MADRS score, indicating that
anxiety in DLB was associated with a slower cognitive
decline than in AD.
There was no significant interaction in patients with
DLB between clinical significant anxiety at baseline and
time on the MMSE, CDR-Global or CDR boxes.
There was a significant interaction between diagnostic
group and time for caregiver-reported anxiety (p = 0.002).
Patients with DLB had a higher level of anxiety at baseline
than patients with AD, but the anxiety level was reduced
over time. This was contrary to patients with AD, among
whom the level of anxiety increased over time, adjusted
for CDR-Global and age (see Fig. 2). There was no signifi-
cant interaction between diagnostic group and time for
self-reported anxiety.
Discussion
In this longitudinal cohort study, we analysed the associ-
ation of anxiety and cognition over 4 years in people
with AD and individuals with DLB. We found no clear
indication that anxiety was associated with a faster
decline in cognition or dementia severity in either the
total sample or in DLB compared with AD, or between
patients with DLB with or without clinical anxiety. The
only observation was that anxiety in DLB was associated
with a slower cognitive decline than in AD.
The level of caregiver-reported anxiety was different
between patients with AD and patients with DLB over
time. During the observation period over 4 years, the
level of anxiety in patients with DLB was declining,
Fig. 1 Flowchart of patient inclusion in the study. AD Alzheimer’s disease, DemVest Dementia Study of Western Norway, DLB dementia with Lewy
bodies, FTD frontotemporal dementia, MCI mild cognitive impairment, PDD Parkinson’s disease dementia, VaD vascular dementia
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which was the opposite of an increasing anxiety level
in patients with AD. Self-reported anxiety was not
found to be different over time.
The observed decline of anxiety in DLB over time
could be due to treatment of anxiety-provoking halluci-
nations or to increased insight and learning how to
interpret the hallucinations as perceptual errors so that
they become pseudo-hallucinations.
Both psychological and biological mechanisms probably
cause the anxiety that occurs in patients with dementia.
Patients with dementia experience less coping in daily
living, lose overview and control, and might fear for the
future [19, 32]. In addition, atrophy and/or dysfunctions
in the limbic structures may make them less capable of
coping with fear and anxiety [18]. Higher levels of cortisol
due to stress can also cause hippocampal atrophy [11].
Furthermore, patients with MCI and anxiety have patho-
logical AD markers in the cerebrospinal fluid which are
not found in patients with depression and MCI, which
may also support a role of biological mechanisms [33].
Even though we did not find that anxiety was associated
with the rate of cognitive decline or dementia sever-
ity, it is important to focus on anxiety to avoid nega-
tive consequences for patients and their caregivers, as
mentioned above. In dementia care, anxiety should be
screened for and, when required, thoroughly mapped
before intervention.
Some limitations of our study should be noted. We
used NPI as the main anxiety measure, which is an
indirect way to measure anxiety via relatives or nurs-
ing home personnel. This is a commonly used and
validated measure in dementia research, but it may
not have satisfactory psychometric properties for
measuring anxiety [19]. In factor analysis of NPI, anx-
iety and depression often load on the same factor. A
majority of the studies have included only patients
with AD, and we found few published studies that
included patients with DLB or analysed them as a
subgroup [34, 35]. In our study, the correlations
between anxiety and other subtests from the NPI at
baseline were low, both in the total sample and in
AD and DLB, but in the longitudinal analysis we
controlled for depression to ensure that an observed
effect from anxiety was not due to a BPSD subsyndrome.
It has been recommended that, when studying anx-
iety in people with dementia, information should be
collected from multiple sources because the caregivers
can report verbalized or behavioural signs of anxiety
but not the internalized symptoms [19]. We therefore
used one item on MADRS to measure self-reported
anxiety, and it is based on the reliability of the patients’
answer. Bradford et al. [36] suggested that people with
mild to moderate dementia can give reliable self-reports
of anxiety symptoms, with validity comparable to reports
obtained from caregivers. In our sample, after 4 years,
34 % had a CDR score of 3, which indicates severe
Table 1 Participant characteristics at baseline
Characteristics Total (n = 194) AD (n = 122) DLB (n = 72) p Value*
Age, yr (SD) 75.8 (7.6) 75.7 (7.8) 76.0 (7.3) 0.951
Women, n (%) 122 (62.9) 90 (73.6) 32 (44.4) <0.001
Education, yr (SD) 9.6 (2.9) 9.6 (3.0) 9.6 (2.9) 0.851
MMSE, mean (SD) 23.5 (2.7) 23.6 (2.3) 23.3 (3.1) 0.693
CDR-Global, median (IQR) 1.0 (0.5) 1.0 (0.5) 1.0 (0.5) 0.071
NPI anxiety, mean (SD) 1.8 (3.0) 1.5 (2.7) 2.2 (3.6) 0.197
NPI depression, mean (SD) 2.0 (2.6) 1.9 (2.5) 2.4 (2.7) 0.147
NPI total, mean (SD) 18.5 (17.3) 15.6 (16.0) 23.7 (18.2) 0.001
MADRS anxiety, median (IQR) 0 (2) 0 (2) 1 (2) 0.109
Clinically significant anxiety, % (median/IQR) 19.9 18.6 (6/4) 22.1 (8/8) 0.237
Non–clinically significant anxiety, % (median/IQR) 80.1 81.4 (0/0) 77.9 (0/1) 0.204
Abbreviations: AD Alzheimer’s disease, DLB Dementia with Lewy bodies, MMSE Mini Mental State Examination, CDR Clinical Dementia Rating, IQR interquartile
range, NPI Neuropsychiatric Inventory, MADRS Montgomery–Åsberg Depression Rating Scale, SD standard deviation
*Differences between the AD and DLB groups were analysed using the Mann-Whitney U test and Pearson’s χ2 test
Fig. 2 Anxiety as evaluated with the Neuropsychiatric Inventory (NPI)
over the course of 4 years in patients with Alzheimer’s disease (AD)
and patients with Lewy bodies (DLB)
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dementia and can challenge the reliability of the score. In
addition, assessing anxiety with only one item from a
depression scale is not optimal and limits the reliabil-
ity of the findings. Observations based only on this
score which are not in accordance with established
research should therefore be carefully weighed.
The MMSE and the CDR scale were used as out-
come measures. MMSE has been criticized for not
being able to adequately monitor cognitive decline in
pure DLB [37]. However, the MMSE was found to be
sensitive for cognitive changes in Parkinson’s disease,
which shares many features with DLB [38]. CDR is
designed for the phenotypes of AD, and less is
known about the psychometric properties when ad-
dressing DLB.
There were also missing data in our analysis, due both
to the inevitable facts that the dementia was progressing
and the patients were not able to participate in the
assessments, and also because of natural mortality
during follow-up. The most appropriate analysis, linear
mixed effects, was used to minimize this problem. There
is still a possibility that the null hypothesis was sup-
ported because of inadequate power. Unfortunately, the
dataset was not large enough to perform joint analysis.
The strengths of our study are that it include a
relatively large number of patients with DLB and that
they were followed annually until death. Patients were
included in the study according to the latest DLB
consortium criteria; they were thoroughly evaluated at
baseline; some also underwent ioflupane single-photon
emission computed tomography; and the diagnosis of
the patients was revised after 2 and 5 years by an
expert panel. Post-mortem autopsies of 36 patients to
date have confirmed the clinical diagnosis, with the
exception of two false-positive cases and one false-
negative case for DLB.
Conclusions
In this study, anxiety was not associated with the dementia
progression rate in AD or DLB. Anxiety gradually de-
creased over 4 years in DLB but gradually increased in
AD. More studies are needed.
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